This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus
by Debanjana Dey
Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.
Thermo Fisher Grows on Coronavirus Diagnostic Tests Amid Crisis
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about ramped up production for its COVID-19 diagnostic test to meet growing global demand.
NuVasive Launches Reline 3D for Pediatric Patients Globally
by Zacks Equity Research
Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.
Medtronic Partners Foxconn to Scale Up Ventilator Production
by Zacks Equity Research
Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.
Henry Schein Dental Software Arm May Rebound Despite Pandemic
by Zacks Equity Research
Henry Schein (HSIC) also seems to be upbeat about its dental technology business, Henry Schein One.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
Illumina Takes Over BlueBee, Fortifies NGS Data Processing
by Zacks Equity Research
With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block
by Zacks Equity Research
With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.
Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes
by Zacks Equity Research
Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.
Abbott's (ABT) FreeStyle Libre Study Outcome Favorable
by Zacks Equity Research
The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.
Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management
by Zacks Equity Research
Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.
Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS
by Zacks Equity Research
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Diagnostic Testing Remains Crucial in Combatting Coronavirus
by Trina Mukherjee
Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.
Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA
by Zacks Equity Research
Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Medtronic's StealthStation Feature Recall Classified Class I
by Zacks Equity Research
This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.
Globus Medical Faces Business Loss Amid Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.